SwePub
Tyck till om SwePub Sök här!
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Friman O.) ;conttype:(refereed)"

Sökning: WFRF:(Friman O.) > Refereegranskat

  • Resultat 1-10 av 30
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Abele, H., et al. (författare)
  • Particle physics at the European Spallation Source
  • 2023
  • Ingår i: Physics reports. - : Elsevier. - 0370-1573 .- 1873-6270. ; 1023, s. 1-84
  • Forskningsöversikt (refereegranskat)abstract
    • Presently under construction in Lund, Sweden, the European Spallation Source (ESS) will be the world’s brightest neutron source. As such, it has the potential for a particle physics program with a unique reach and which is complementary to that available at other facilities. This paper describes proposed particle physics activities for the ESS. These encompass the exploitation of both the neutrons and neutrinos produced at the ESS for high precision (sensitivity) measurements (searches).
  •  
2.
  • Friman, Styrbjörn, 1948, et al. (författare)
  • Long-term, Prolonged-release Tacrolimus-based Immunosuppression in De Novo Liver Transplant Recipients: 5-year Prospective Follow-up of Patients in the DIAMOND Study
  • 2021
  • Ingår i: Transplantation Direct. - : Ovid Technologies (Wolters Kluwer Health). - 2373-8731. ; 7:8
  • Tidskriftsartikel (refereegranskat)abstract
    • Background. Immunosuppression with calcineurin inhibitors (CNIs) is reportedly associated with risk of renal impairment in liver transplant recipients. It is believed that this can be mitigated by decreasing initial exposure to CNIs or delaying CNI introduction until 3-4 d posttransplantation. The ADVAGRAF studied in combination with mycophenolate mofetil and basili ximab in liver transplantation (DIAMOND) trial evaluated different administration strategies for prolonged-release tacrolimus (PR-T). Methods. DIAMOND was a 24-wk, open-label, phase 3b trial in de novo liver transplant recipients randomized to: PR-T 0.2 mg/kg/d (Arm 1); PR-T 0.15-0.175 mg/kg/d plus basiliximab (Arm 2); or PR-T 0.2 mg/kg/d delayed until day 5 posttransplant plus basiliximab (Arm 3). In a 5-y follow-up, patients were maintained on an immunosuppressive regimen according to standard clinical practice (NCT02057484). Primary endpoint: graft survival (Kaplan-Meier analysis). Results. Follow-up study included 856 patients. Overall graft survival was 84.6% and 73.5% at 1 and 5 y post transplant, respectively. Five-year rates for Arms 1, 2, and 3 were 74.7%, 71.5%, and 74.5%, respectively. At 5 y, death-censored graft survival in the entire cohort was 74,7%. Overall graft survival in patients remaining on PR-T for z30 d was 79.1%. Graft survival in patients who remained on PR-T at 5 y was 87.3%. Patient survival was 86.6% at 1 y and 76.3% at 5 y, with survival rates similar in the 3 treatment arms at 5 y. Estimated glomerular filtration rate at the end of the 24-wk initial study and 5 y posttransplant was 62.1 and 61.5 mi./min/1.73 m(2), respectively, and was similar between the 3 treatment arms at 5 y. Overall, 18 (2.9%) patients had z1 adverse drug reaction, considered possibly related to PR-T in 6 patients. Conclusions. In the DIAMOND study patient cohort, renal function, graft survival, and patient survival were similar between treatment arms at 5 y posttransplant.
  •  
3.
  •  
4.
  • Backman, Filip, 1991-, et al. (författare)
  • The development of the NNBAR experiment
  • 2022
  • Ingår i: Journal of Instrumentation. - : Institute of Physics (IOP). - 1748-0221 .- 1748-0221. ; 17:10
  • Tidskriftsartikel (refereegranskat)abstract
    • The NNBAR experiment for the European Spallation Source will search for free neutrons converting to antineutrons with a sensitivity improvement of three orders of magnitude compared to the last such search. This paper describes progress towards a conceptual design report for NNBAR. The design of a moderator, neutron reflector, beamline, shielding and annihilation detector is reported. The simulations used form part of a model which will be used for optimisation of the experiment design and quantification of its sensitivity.
  •  
5.
  •  
6.
  •  
7.
  •  
8.
  •  
9.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 30
Typ av publikation
tidskriftsartikel (26)
rapport (1)
konferensbidrag (1)
forskningsöversikt (1)
bokkapitel (1)
Typ av innehåll
refereegranskat  (30)Ta bort avgränsningen
Författare/redaktör
Larsson, E (5)
Meirose, Bernhard (4)
Bell, M. (4)
Wagner, R (4)
Zanini, L (4)
Fierlinger, P. (4)
visa fler...
Friman-Gayer, U. (4)
Holl, M. (4)
Kamyshkov, Y. (4)
Rataj, B. (4)
Rizzi, N. (4)
Santoro, V. (4)
Takibayev, A. (4)
Zimmer, O. (4)
Oskarsson, A. (3)
Brooijmans, G. (3)
Bohm, Christian, 194 ... (3)
Dunne, Katherine (3)
Eklund, Lars (3)
Kupsc, Andrzej (3)
Eriksson, L (3)
Kolevatov, R. (3)
Perrey, H. (3)
Klinkby, E. (3)
Ferreira, M. J. (3)
Bianchi, A. (3)
Calén, Hans (3)
Happe, C. (3)
Nepomuceno, A. (3)
Nilsson, Thomas, 196 ... (3)
Wolke, Magnus (3)
Yiu, Sze-Chun (3)
Young, A. R. (3)
Cooray, C (3)
Friman, Styrbjörn, 1 ... (3)
Oldner, A (3)
Silverstein, Samuel ... (2)
Milstead, David A. (2)
Ericzon, BG (2)
Barrow, J. (2)
Bentley, P. (2)
Beßler, Y. (2)
Damian, J. I. M. (2)
Di Julio, D. D. (2)
Muhrer, G. (2)
Schober, H. (2)
Wolke, M. (2)
Eriksson, M (2)
Cederkäll, J. (2)
Johansson, Tord (2)
visa färre...
Lärosäte
Karolinska Institutet (13)
Uppsala universitet (9)
Karlstads universitet (5)
Göteborgs universitet (4)
Stockholms universitet (4)
Lunds universitet (4)
visa fler...
Chalmers tekniska högskola (3)
Kungliga Tekniska Högskolan (2)
Linköpings universitet (2)
Luleå tekniska universitet (1)
visa färre...
Språk
Engelska (30)
Forskningsämne (UKÄ/SCB)
Samhällsvetenskap (5)
Naturvetenskap (4)
Medicin och hälsovetenskap (3)
Teknik (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy